Aurobindo Pharma Limited has informed the Exchange regarding a press release dated March 04, 2026, titled "Eugia Pharma announces launch of Pomalidomide Capsules in the US".
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma's wholly-owned subsidiary Eugia Pharma Specialities has launched Pomalidomide Capsules (1mg, 2mg, 3mg, and 4mg) in the US market. The product is a generic version of Bristol-Myers Squibb's Pomalyst, used to treat relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma. Eugia was one of the First-to-File (FTF) ANDA applicants, which typically grants 180 days of market exclusivity. The US market for Pomalidomide Capsules is estimated at approximately US$ 3.3 billion, based on IQVIA MAT data for the twelve months ending January 2026.
This launch positions Aurobindo to capture share in a US$ 3.3 billion US market, with FTF status providing a key competitive edge and likely exclusivity benefits. Positive for the company's US generics revenue, though actual revenue capture will depend on pricing dynamics and competition after the exclusivity period.